Conclusions These preliminary findings indicate that objective responses in Phase I trials may have predictive value for later regulatory approval.
Introduction
The development of effective new treatments for cancer remains expensive and challenging. This is because a majority of new agents in oncology do not succeed in gaining Food and Drug Administration (FDA) approval [1, 2] . A high failure rate in oncology drug development highlights the severe limitations of current methods of prediction for future regulatory approval [3] . Some difficulties in oncology drug development are due to a shift from cytotoxic to molecularly targeted agents, availability of several new potential drug combinations and a plethora of newly recognized pathways that could be therapeutically targeted. A high number of negative Phase III studies and regulatory setbacks have a negative impact on the confidence level of investigators as well investors in the pharmaceutical industry. Considering the high cost involved in developing new therapeutics, a prediction tool to guide which agents proceed forward after completion of Phase I study is needed. However, Phase I trials are not statistically designed for efficacy analysis and therefore differ from Phase II or III studies in several respects including the primary endpoint, dose range, patient population and baseline characteristics such as disease status, severity and age. With all the pitfalls, still there is a growing interest to extrapolate efficacy findings from these data. Therefore, the purpose of our analysis was to identify the characteristics and outcomes of published Phase I studies associated with future FDA approval.
Abstract
Purpose Drug development in oncology is resource intensive and has a high failure rate. In this exploratory analysis, we aimed to identify the characteristics and outcomes of published Phase I studies associated with future Food and Drug Administration (FDA) approval. Methods Phase I studies of approved and non-approved anticancer agents between 2000 and 2013 were retrospectively examined. Fisher's exact and chi-squared tests were used to compare the potential predictive measures. Results Phase I studies of 88 anticancer agents (54 approved and 34 non-approved by the FDA), treating a total of 4,423 subjects, were examined. The median number of patients in Phase I trials of approved and non-approved agents was 44.5 and 32, respectively. A total of 423 subjects (86 reporting studies) had a complete responses, and 342 subjects (80 reporting studies) had a partial responses (PR). A higher number of PR (P < 0.001), PR rate (P = 0.003) and longer PR duration (P = 0.001) were predictive of regulatory success.
Materials and methods
We compared the characteristics of published Phase I studies of both FDA approved and non-approved agents. Phase I studies of cytotoxic drugs between 2000 and 2013 were identified by searching PubMed, relevant oncology journals, and the oncologic drugs advisory committee (ODAC) Web site. Figure 1 summarizes the literature search and agent identification process (as of November 2013). Agents that had not proceeded to Phase III testing because of lack of clinical activity were excluded. This would screen out agents, which had not demonstrated an efficacy signal or abandoned due to other reasons without further development. The selected agents (listed in Supplementary Appendix) were placed into approved or non-approved categories, based on their FDA regulatory status [4] . Agents with approval in multiple tumor types were included only once at the time of their initial FDA approval. Phase Ib trials, Phase I trials of radiopharmaceuticals, supportive drugs, drug devices, endocrine agents and vaccines were excluded. For the included agents, details on the number of patients in study, response rates (complete, confirmed partial and stable disease), duration of response and dose at which the response occurred were retrieved. Responses were classified according to the description in the published study (RECIST or WHO criteria) [5] [6] [7] . We then examined trial characteristics and outcomes associated with future FDA approval or non-approval. Fisher's exact and chi-squared tests were used to compare the potential predictive measures.
Results
Phase I results of 88 new agents treating a total of 4,423 subjects met the eligibility criteria (54 approved and 34 non-approved by the FDA). The median number of patients in Phase I trials of approved and non-approved agents was 44.5 and 32, respectively. A total of 423 subjects (from 86 
N=143
Full-text articles of Phase I studies of eligible Agents retrieved from the journal or Pub Med N=88 reporting studies) had a complete responses (CR), and 342 subjects had a PR (from 80 reporting studies). A higher number of PR (P < 0.001), PR rate (P = 0.003) and longer PR duration (P = 0.001) were predictive of regulatory success (Table 1) . A positive trend toward higher regulatory success was observed for studies with larger sample size (P = 0.053), higher CR rate (P = 0.049) and number of patients with stable disease (P = 0.047). There were no statistically significant differences in stable disease rate and duration of CRs between the two groups. Studies that had ≥3 subjects with a PR (P < 0.001) or ≥3 % of subjects with a PR (P = 0.001) in Phase I trials were more likely to eventually receive FDA approval.
Discussion
If an agent had no response in the Phase I trial, our study showed that it has a low likelihood of being approved. Eribulin mesylate (Halaven ® ), pemetrexed (Alimta ® ) and vandetanib (Caprelsa ® ) are the only three approved agents in this analysis without an objective response in the first Phase I trials [8] [9] [10] . However, confirmed partial responses (PR) were observed in the subsequent Phase I trials of these agents using similar or different schedules [11] [12] [13] . Previously, Von Hoff et al. in an analysis of 113 chemotherapeutic agents from 1970 to 1983 reported that the FDA approved agents were associated with a median of six responses in the Phase I trials [14] .
As recently reported, we observed that it involved an average of 6 years from the start of Phase I study until approval of the agent [15] . Given the high unmet need in oncology, new drugs with a favorable benefit-to-harm balance should become available to patients more rapidly. Newer FDA initiatives such as breakthrough therapy designation and the accelerated approval program may expedite the future drug approval process. However, the rapid approval and withdrawal of some drugs recently illustrate ongoing challenges of these programs [16, 17] . Some observers have proposed routine adoption of randomized designs in Phase I and II trials to make the development process more efficient [18] . Admittingly, the extent of therapeutic benefit from uncontrolled studies is difficult to interpret accurately; it could be argued at the same time that Phase I studies only offer basic guidance for the design of subsequent randomized trials. There are several limitations of our analysis including retrospective methodology, heterogeneity of agents, a possibility of publication bias due to our reliance on published data only, preselection of agents with positive track record, non-uniform data collection and reporting among published studies. To ameliorate the effect of publication bias, a serious effort should be made to publish all clinical trial results in a consistent manner, regardless of outcome. We have identified some areas of future work as these data lead to an interesting, but challenging future direction. These findings could be extended to different types of cancers, similar review of Phase II studies and development of a prediction model by incorporating all the characteristics of drug response in the target population. This may allow a more formal synthesis of the data and knowledge available at the end of Phase I or II study and contribute to a better and more successful drug development, from a regulatory, industry and academic standpoint.
